Arndt Vogel: Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X about a recent paper by him and colleagues published in JHEP Reports:
“Off the press:
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC JHEP Reports:
- International observational study
- Easy to use tool to predict outcome.”
Authors: Dongdong Xia, Wei Bai, Qiuhe Wang, Arndt Vogel, Guohong Han et al.
More posts featuring Arndt Vogel.
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.
He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023